174 related articles for article (PubMed ID: 35954297)
21. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
[TBL] [Abstract][Full Text] [Related]
22. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
23. The bisecting GlcNAc in cell growth control and tumor progression.
Miwa HE; Song Y; Alvarez R; Cummings RD; Stanley P
Glycoconj J; 2012 Dec; 29(8-9):609-18. PubMed ID: 22476631
[TBL] [Abstract][Full Text] [Related]
24. N-glycoproteins bearing beta1-6 branched oligosaccharides from the A375 human melanoma cell line analysed by tandem mass spectrometry.
Ochwat D; Hoja-Łukowicz D; Lityńska A
Melanoma Res; 2004 Dec; 14(6):479-85. PubMed ID: 15577318
[TBL] [Abstract][Full Text] [Related]
25. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.
Nakano M; Nakagawa T; Ito T; Kitada T; Hijioka T; Kasahara A; Tajiri M; Wada Y; Taniguchi N; Miyoshi E
Int J Cancer; 2008 May; 122(10):2301-9. PubMed ID: 18214858
[TBL] [Abstract][Full Text] [Related]
26. Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer via Down-Regulation of EGFR/Erk Signaling.
Cheng L; Cao L; Wu Y; Xie W; Li J; Guan F; Tan Z
Front Oncol; 2020; 10():929. PubMed ID: 32612952
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycans.
Stanley P; Sundaram S; Tang J; Shi S
Glycobiology; 2005 Jan; 15(1):43-53. PubMed ID: 15329358
[TBL] [Abstract][Full Text] [Related]
28. Analytically validated protein biomarkers of chronic pancreatitis and pancreatic cancer for potential clinical diagnosis with mass spectrometry.
Chou CY; Chang CT; Chen CJ
Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1():e8580. PubMed ID: 31502717
[TBL] [Abstract][Full Text] [Related]
29. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
31. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
[TBL] [Abstract][Full Text] [Related]
32. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera.
Zhao J; Patwa TH; Qiu W; Shedden K; Hinderer R; Misek DE; Anderson MA; Simeone DM; Lubman DM
J Proteome Res; 2007 May; 6(5):1864-74. PubMed ID: 17428079
[TBL] [Abstract][Full Text] [Related]
33. Profiling the N-Glycan Composition of IgG with Lectins and Capillary Nanogel Electrophoresis.
Lu G; Holland LA
Anal Chem; 2019 Jan; 91(2):1375-1383. PubMed ID: 30525457
[TBL] [Abstract][Full Text] [Related]
34. Characterisation of N-glycans bound to IGFBP-3 in sera from healthy adults.
Masnikosa R; Baricević I; Lagundzin D; Nedić O
Biochimie; 2010 Jan; 92(1):97-101. PubMed ID: 19800385
[TBL] [Abstract][Full Text] [Related]
35. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
[TBL] [Abstract][Full Text] [Related]
38. Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.
Shah AK; Cao KA; Choi E; Chen D; Gautier B; Nancarrow D; Whiteman DC; Saunders NA; Barbour AP; Joshi V; Hill MM
Mol Cell Proteomics; 2015 Nov; 14(11):3023-39. PubMed ID: 26404905
[TBL] [Abstract][Full Text] [Related]
39. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study.
Xu J; Cao Z; Liu W; You L; Zhou L; Wang C; Lou W; Sun B; Miao Y; Liu X; Zhang T; Zhao Y
Ann Surg; 2016 Jun; 263(6):1173-9. PubMed ID: 26114496
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry.
Ahn YH; Lee JY; Lee JY; Kim YS; Ko JH; Yoo JS
J Proteome Res; 2009 Sep; 8(9):4216-24. PubMed ID: 19645485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
